Mizuho Maintains Outperform on LeonaBio, Lowers Price Target to $15
Mizuho analyst Graig Suvannavejh maintains LeonaBio (NASDAQ:LONA) with a Outperform and lowers the price target from $16 to $15.
Stocks · News reference
LeonaBio Enrolls 500th Subject In Phase 3 ELAINE-3 Trial For Lasofoxifene With Abemaciclib
On August 26, 2026, LeonaBio, Inc. (the "Company") announced that it had enrolled the 500th subject in its ongoing Phase 3 ELAINE-3 clinical trial (NCT05696626) for lasofoxifene in combination with abemaciclib,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citizens Maintains Market Outperform on LeonaBio, Lowers Price Target to $17
Citizens analyst Jason N. Butler maintains LeonaBio (NASDAQ:LONA) with a Market Outperform and lowers the price target from $18 to $17.
LeonaBio Q2 EPS $(0.80) Beats $(1.36) Estimate
LeonaBio (NASDAQ:LONA) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.36) by 41.18 percent. This is a 55.56 percent increase over losses of $(1.80) per share from the